Access (or not) to vaccines for mpox in Africa: a sense of déjà vu?

The current multi-country outbreak of mpox, formerly known as monkeypox, which started in Europe in early May 2022 and spread to more than 90 countries by August, has garnered worldwide attention and concern. Mpox is endemic to Africa, and the widespread transmission to so many non-endemic countries in such a short period of time has been unprecedented.

In response to this, on July 23, 2022, the World Health Organization (WHO) took the extraordinary step of declaring mpox a Public Health Emergency of International Concern (PHEIC), which should allow for more resources to be made available to control the outbreak and require a more coordinated international response, including possibly encouraging nations to share vaccines to protect people against the disease.

However, will we learn the lessons from the COVID-19 pandemic, another PHEIC, and address the vast inequities in global vaccine distribution that left much of the Global South waiting for COVID-19 vaccines, or will there be a terrible sense of déjà vu with people in endemic African countries left at the back of the queue once more?

Mpox outbreaks endemic to West and Central Africa

While most people in the world had never heard of mpox up until a few months ago, MSF has experience treating people with this neglected disease in our projects, most recently in Central African Republic in 2018. So while it’s not a new disease for MSF medical teams, the current scramble to get vaccines for mpox is.

Mpox belongs to the family of viruses that includes smallpox virus, with symptoms similar to smallpox but clinically less severe. The first human case of mpox was identified in the Democratic Republic of Congo (DRC) in 1970, and human cases have been reported in 11 countries in West and Central Africa.

What has been lost in all the media hype is the ongoing mpox outbreak in Africa that predates the current pandemic. Mpox has been causing regular outbreaks in communities in Central and West Africa for decades. Evidence suggests that case numbers have been on the rise in recent years, but warning signs were largely overlooked.

DRC has been most affected by mpox and is the only nation that has continually reported cases over the past five decades. There was a surge in the country in 2020, with 6,216 suspected cases and 222 deaths reported. Nigeria, the second-most affected country, has had an ongoing outbreak since September 2017, with a total of 558 suspected cases reported from 32 states in the country and eight deaths until April 30, 2022. Since May 2022, Nigeria has had four confirmed mpox deaths, the highest of any other country to date in this worldwide epidemic.

Vaccine protection against mpox

Fortunately, tools to prevent mpox exist. Vaccines designed for smallpox will likely provide a degree of cross-protection to mpox. Second-generation smallpox vaccines like ACAM2000 have significant side effects, but a newer third-generation smallpox vaccine, MVA-BN, has come along recently with a much better safety profile, and thus is the preferred vaccine to use in this outbreak. It is licensed for use against mpox in the US and the EU (under the names Jynneos and Imvanex, respectively).

Currently over 116 million vaccine doses are estimated to be scattered among various national stockpiles, mainly because of fears of a bioterrorism attack with smallpox. This includes about 100 million doses of the ACAM2000 vaccine, and about 16.4 million doses of MVA-BN, most of which are held by the US.

Prior to this current outbreak, wealthy nations had committed to share 31 million doses of vaccine if requested by WHO as part of the Smallpox Vaccine Emergency Stockpile in a time of international need; the status of this agreement and what is happening with those doses are unclear. WHO has said it is developing a vaccine-sharing mechanism, but details have been sparse, and as of the time of writing, no countries have yet shared any doses.

Despite the existence of these stockpiles, the recent issues with COVID-19 vaccine access in low- and middle-income countries (LMICs) provide some valuable lessons. In 2020, even before COVID-19 vaccines were developed, high-income countries (HICs) started placing large orders for the first candidate vaccines. When the vaccines were finally manufactured, most of the supply was already sold/pre-allocated to the HICs who could pay top dollar up front.

Meanwhile, the COVAX Facility, a mechanism set up to provide equitable allocation of limited vaccines to all countries, including LMICs, was put at the back of the line. This resulted in HICs purchasing excessive amounts of COVID-19 vaccines, such that many were able to fully vaccinate and boost much of their populations before governments in LMICs could vaccinate even their high-risk populations. We are already seeing HICs putting in large orders for the MVA-BN vaccine.

We must not let this situation be repeated with mpox.

Price and supply barriers to new vaccine

What’s clearly needed now is an affordable supply of vaccines to be made available to endemic African countries if and when they need it. While pricing information is hard to come by, according to some senior health officials, the MVA-BN mpox vaccine is priced at $100 a dose, which is unaffordable for people in LMICs and would make them (once again) dependent upon vaccine donations from HICs. However, lower prices are not guaranteed. Even though the development of the vaccine was heavily funded by the US government to the tune of $2 billion, control over the price and availability of this vaccine remains with the company, Bavarian Nordic, which holds a patent monopoly on the vaccine.

This dependence on a single manufacturer for the vaccine is already proving potentially disastrous. Bavarian Nordic has recently stated that they are uncertain they can meet the current demand, and are now considering a technology transfer to a US manufacturer.

But what is really needed to address equity is technology transfer to a company on the African continent so that African nations do not have to depend solely on donations from HICs. South Africa’s Aspen Pharmacare has offered to support the fill and finish of mpox vaccines, but receiving a full technology transfer could go much further to enabling African self-sufficiency over the longer term. Additionally, endemic countries will also need the programmatic support to administer the vaccines while not drawing resources away from already strained health care systems.

We cannot expect people in West and Central Africa to get equitable access to vaccines with the current manufacturing monopoly scenario and dependence on vaccine dose donations. As COVID-19 recedes and the numbers of mpox cases potentially rise, the sense of déjà vu will become ever more pronounced. Without action now, the gap between people who have access to vaccines, and those who do not, will widen once more.